Advertisement
Advertisement
TOPIC

Biomedicine: Companies

Related Topics:
Biomedicine: Companies
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
The lawsuit seeks WuXi’s removal from the Pentagon blacklist. Photo illustration: Reuters
US-China relations

Biotech firm WuXi sues US over allegations it supports China’s military

The company says it suffered substantial reputational and operational harm after being placed on a Pentagon blacklist.

videocam
China’s private sector

China biotech firms say global push is ‘irreversible’ despite US barriers

China’s private sector

Chinese pharmaceutical firms’ cost advantages trump Pentagon blacklist: analysts

China’s private sector

Which company could become the Chinese Pfizer? Here are analysts’ top picks

A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands.

Chinese pharmaceutical companies may expand into international markets in the coming years. Photo: Shutterstock
China’s private sector

With AI able to predict disease, can we treat ageing like a ‘bug’ in the system?

AI is transforming longevity as companies like METiS TechBio and Human Longevity use algorithms to combat ageing and predict health risks.

Hong Kong stock market

GenScript rally underscores China’s rise in cancer drug innovation

The share-price surge came as promising cancer trial data overshadowed continuing scrutiny of China’s biotechnology sector by US lawmakers.

Advertisement
Advertisement
Advertisement
Science

Biomedicine | China steps up Alzheimer’s, Parkinson’s drug push, looks to TCM

With the most cases of the two leading neurodegenerative diseases, and affected population rising as country ages, China needs to find new treatments.

China steps up Alzheimer’s, Parkinson’s drug push, looks to TCM
China’s private sector

Akeso lung cancer drug trial raises hopes in US$20b market

Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

Biomedicine: Industry Trends

China’s Innovent Biologics signs US$10.5b Pfizer deal for 12 cancer drug trials

The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer.

videocam
Science

Chinese team uses supercomputer to cut drug screening time from years to seconds

AI platform that can screen vast library of chemical compounds opens up new frontiers in fight against cancer and infectious diseases.

videocam
Innovative drug research and development typically takes more than 10 years to yield results. Photo: Shutterstock
China’s private sector

China’s biotech boom drives surge in home-grown innovative drug approvals

Domestic firms dominate China’s drug approvals amid jump in spending and out-licensing deals as regulator speeds path to market.

Chinese biotech firms struck a record US$60 billion in cross-border licensing deals in the first quarter of 2026. Photo: Getty Images
China’s private sector

Insilico, US partner to build AI models predicting disease decades ahead

Tie-up combines Hong Kong-listed Insilico Medicine’s algorithms with Human Longevity’s genomic data to advance personalised health research.

Banking & finance

Hong Kong-listed firm uses AI to make nano-rockets to deliver life-saving drugs

METiS TechBio debuts on Hong Kong stock market as its CEO compares the drug design start-up to SpaceX for the pharmaceutical industry.

videocam
China’s private sector

China’s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS

Company’s shares jump in Hong Kong and Shenzhen after tie-up that bolsters China’s growing drug innovation profile.

A worker checks a feeding tray at the Hengrui Biomedical Industrial Park in Lianyungang, east China’s Jiangsu province. Photo: Getty Images
Artificial intelligence

ByteDance’s drug unit presents AI-designed therapies at global conferences

Chinese tech giant fields teams in Boston, Rio de Janeiro and Barcelona as its unit unveils frameworks and therapies powered by AI.

ByteDance has doubled down on AI despite a 70 per cent profit plunge in 2025. Photo: Shutterstock
Hong Kong company reporting season

WuXi AppTec shares surge 14% in Hong Kong after record first-quarter earnings

The Chinese company’s revenue rose nearly 29 per cent to 12.44 billion yuan, while profit surged about 27 per cent to 4.65 billion yuan.

United States

US FDA plans ultra-fast review of 3 psychedelic drugs after Trump directive

The recent moves on psychedelics reflect growing popular support for the mind-altering substances among Trump’s supporters.

Advertisement
Advertisement
Advertisement
Banking & finance

Biotech-led boom as 8 China firms flock to Hong Kong’s thriving stock market

AI-powered drug developer Metis TechBio leads group that includes developers of autonomous driving technology and industrial robots.

Healthcare led liquidity growth on the Hong Kong stock market over the past decade, with trading turnover for the sector surging more than 11-fold between 2015 and 2025. Photo: Shutterstock
China’s private sector

How China’s ‘landmark’ drug pricing guidelines could be a boon for biotech

State Council calls for ‘value-based pricing’ for innovative drugs, a move researchers said would benefit private healthcare players.

China’s private sector

Chinese drug makers take on Western dominance in US$16 billion Parkinson’s race

The future of treating brain diseases could lie in non-invasive technologies, according to Chongqing Haifu Medical Technology.

China’s private sector

China’s drug makers are speeding up – will AI be their secret weapon?

Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?

Illustration by Henry Wong
Banking & finance

China healthcare stocks shine in Hong Kong amid Middle East turmoil

Hang Seng Healthcare Index outpaces broader market as Akeso, Innovent, Hansoh provide refuge for global investors.

A number of Chinese biopharmaceutical and biotech companies posted their first-ever annual profits in 2025. Photo: Shutterstock
Banking & finance

Everest’s US$250 million buy signals rising global appetite for China biotech

Sovereign wealth funds from Singapore and Abu Dhabi join Chinese state capital as cross-border biotech licensing reaches record highs.

Biomedicine: Geopolitics

Global drug makers face pricing pressure as China targets affordable healthcare

As pharmaceutical firms navigate China’s aggressive pricing reforms, their profits could be squeezed further this year.

5
Banking & finance

Stricter Chinese scrutiny of offshore vehicles a blow for tech IPO candidates

Mainland’s stock market watchdog is discouraging establishment of ‘red-chip-structured’ companies in sensitive industries.

Many Chinese biotech and tech firms favour red-chip structures. Photo: Shutterstock
Banking & finance

Chinese company to use AI-powered testing to boost profits and fast-track IVF

China’s falling fertility rate sees spike in demand for assisted reproduction as biotech firm raises US$101 million from Hong Kong listing.

videocam
A Chinese biotech company is hoping AI technology will help to boost profits and speed up chromosome testing which is a vital part of In vitro fertilisation. Photo: Dreamstime/TNS
Banking & finance

Insilico Medicine signs AI drug development deal with Eli Lilly

Reaching development, regulatory and commercial milestones could see value of deal hit around US$2.75 billion.

China’s private sector

Li Ka-shing’s CK Life unit eyes China fast track for cancer vaccine pipeline

Sequencio, CK Life’s new Hong Kong unit, is advancing about 20 cancer vaccine projects as China pathway offers faster route to human trials.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement